PhIII Alzheimer’s drug goes bust — and a major setback at Eli Lilly and AstraZeneca may doom the class
Another big Phase III Alzheimer’s program is being scrapped at Eli Lilly $LLY and AstraZeneca $AZN, offering fresh evidence that the entire BACE class may …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
